Clin Exp Pharmacol Physiol Suppl. 1982;6:89-96.
The reasons for starting a trial of verapamil in early intervention of acute myocardial infarction (AMI) are reviewed. In a pilot study of sixty-one patients it was demonstrated that verapamil probably had no harmful effects in patients with AMI. A multicentre study is now in progress in Denmark; 1433 have been included. Patients are treated with either placebo or verapamil 120 mg three times a day for 6 months. The results of the study, that is effect of verapamil treatment on death and reinfarction, will be available in 1982.
本文回顾了在急性心肌梗死(AMI)早期干预中开展维拉帕米试验的原因。在一项针对61例患者的初步研究中,已证明维拉帕米对AMI患者可能没有有害影响。丹麦目前正在进行一项多中心研究;已纳入1433例患者。患者接受安慰剂或每天三次、每次120毫克维拉帕米治疗,为期6个月。该研究关于维拉帕米治疗对死亡和再梗死影响的结果将于1982年公布。